AU2006218489B2 - KIM-1 antibodies for treatment of Th2-mediated conditions - Google Patents

KIM-1 antibodies for treatment of Th2-mediated conditions Download PDF

Info

Publication number
AU2006218489B2
AU2006218489B2 AU2006218489A AU2006218489A AU2006218489B2 AU 2006218489 B2 AU2006218489 B2 AU 2006218489B2 AU 2006218489 A AU2006218489 A AU 2006218489A AU 2006218489 A AU2006218489 A AU 2006218489A AU 2006218489 B2 AU2006218489 B2 AU 2006218489B2
Authority
AU
Australia
Prior art keywords
antibody
seq
antigen
amino acids
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006218489A
Other languages
English (en)
Other versions
AU2006218489A1 (en
Inventor
Veronique Bailly
Alexey Lugovskoy
Patricia Mccoon
Paul D. Rennert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of AU2006218489A1 publication Critical patent/AU2006218489A1/en
Application granted granted Critical
Publication of AU2006218489B2 publication Critical patent/AU2006218489B2/en
Priority to AU2011202405A priority Critical patent/AU2011202405B2/en
Assigned to BIOGEN MA INC. reassignment BIOGEN MA INC. Request to Amend Deed and Register Assignors: BIOGEN IDEC MA INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2006218489A 2005-03-02 2006-03-02 KIM-1 antibodies for treatment of Th2-mediated conditions Ceased AU2006218489B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2011202405A AU2011202405B2 (en) 2005-03-02 2011-05-24 KIM-1 Antibodies for Treatment of TH2-mediated Conditions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65778905P 2005-03-02 2005-03-02
US60/657,789 2005-03-02
PCT/US2006/007441 WO2006094134A2 (en) 2005-03-02 2006-03-02 Kim-1 antibodies for treatment of th2-mediated conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2011202405A Division AU2011202405B2 (en) 2005-03-02 2011-05-24 KIM-1 Antibodies for Treatment of TH2-mediated Conditions

Publications (2)

Publication Number Publication Date
AU2006218489A1 AU2006218489A1 (en) 2006-09-08
AU2006218489B2 true AU2006218489B2 (en) 2011-02-24

Family

ID=36648475

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2006218489A Ceased AU2006218489B2 (en) 2005-03-02 2006-03-02 KIM-1 antibodies for treatment of Th2-mediated conditions
AU2011202405A Ceased AU2011202405B2 (en) 2005-03-02 2011-05-24 KIM-1 Antibodies for Treatment of TH2-mediated Conditions

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2011202405A Ceased AU2011202405B2 (en) 2005-03-02 2011-05-24 KIM-1 Antibodies for Treatment of TH2-mediated Conditions

Country Status (14)

Country Link
US (2) US8206705B2 (cg-RX-API-DMAC7.html)
EP (2) EP1865985B1 (cg-RX-API-DMAC7.html)
JP (2) JP2008531719A (cg-RX-API-DMAC7.html)
KR (1) KR101213894B1 (cg-RX-API-DMAC7.html)
CN (2) CN101166542A (cg-RX-API-DMAC7.html)
AT (1) ATE478707T1 (cg-RX-API-DMAC7.html)
AU (2) AU2006218489B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0608254A2 (cg-RX-API-DMAC7.html)
CA (1) CA2599967C (cg-RX-API-DMAC7.html)
DE (1) DE602006016413D1 (cg-RX-API-DMAC7.html)
IL (1) IL185653A (cg-RX-API-DMAC7.html)
NZ (1) NZ562045A (cg-RX-API-DMAC7.html)
WO (1) WO2006094134A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200708372B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008064031A2 (en) * 2006-11-13 2008-05-29 Government Of The United States, As Represented Bythe Secretary Of The Department Of Health And Human Services Potent activation of antigen presenting cells by the hepatitis a virus cellular receptor 1 and its role in the regulation of immune responses
CA2833785C (en) 2011-04-21 2022-06-07 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for the treatment of neuromyelitis optica
MA43135A (fr) 2015-10-30 2018-09-05 Aleta Biotherapeutics Inc Compositions et méthodes pour le du traitement du cancer
BR112018008390A2 (pt) 2015-10-30 2018-11-27 Aleta Biotherapeutics Inc composições e métodos para transdução tumoral

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098920A1 (en) * 2001-06-01 2002-12-12 Biogen, Inc. Molecules and methods for inhibiting shedding of kim-1
WO2004060041A2 (en) * 2002-12-30 2004-07-22 Biogen Idec Ma Inc. Kim-1 antagonists and use to modulate immune system
WO2004084823A2 (en) * 2003-03-19 2004-10-07 Abgenix, Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
ATE182625T1 (de) 1993-01-12 1999-08-15 Biogen Inc Rekombinante anti-vla4 antikörpermoleküle
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5622861A (en) 1994-08-05 1997-04-22 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA encoding hepatitis A virus receptor
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US6165733A (en) 1996-05-23 2000-12-26 Chiron Corporation γ II adaptin
CN1147584C (zh) 1996-05-24 2004-04-28 拜奥根有限公司 组织再生调节物
JP2001503271A (ja) 1996-11-01 2001-03-13 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド ヒト粘膜アドレシン細胞接着分子―１（ＭＡｄＣＡＭ―１）およびそのスプライス変異体
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
CA2274250A1 (en) 1996-12-06 1998-06-11 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1.beta. converting enzyme
CN101274962A (zh) 1998-01-23 2008-10-01 霍夫曼-拉罗奇有限公司 人il-12抗体
KR20010041765A (ko) 1998-03-11 2001-05-25 가마쿠라 아키오 ＩｇＥ 항체생산 억제제 및 자기면역질환 억제제
US6228642B1 (en) 1998-10-05 2001-05-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
ATE425249T1 (de) 2000-06-16 2009-03-15 Biogen Idec Inc Renale regulatorische elemente und deren verwendung
US7838220B2 (en) 2001-06-29 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes associated with immune disease
US7553939B2 (en) 2001-06-29 2009-06-30 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes and methods of use thereof
EP1434881A4 (en) 2001-09-17 2005-10-26 Protein Design Labs Inc METHOD FOR DIAGNOSIS OF CANCER COMPOSITIONS AND METHOD FOR SCREENING ON CANCER MODULATORS
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US7687454B2 (en) 2001-12-03 2010-03-30 The University Of British Columbia Effectors of innate immunity determination
WO2003063792A2 (en) 2002-01-30 2003-08-07 The Brigham And Women's Hospital, Inc. Compositions and methods related to tim-3, a th1-specific cell surface molecule
US20050014687A1 (en) 2002-03-19 2005-01-20 Anderson David W. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
GB0215509D0 (en) 2002-07-04 2002-08-14 Novartis Ag Marker genes
WO2005001092A2 (en) 2003-05-20 2005-01-06 Wyeth Compositions and methods for diagnosing and treating cancers
TW200539890A (en) 2004-03-12 2005-12-16 Brigham & Womens Hospital Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
CA2560941A1 (en) 2004-03-24 2005-10-20 Telos Pharmaceuticals Llc Compositions as adjuvants to improve immune responses to vaccines and methods of use
US8025557B2 (en) 2009-02-27 2011-09-27 Illinois Tool Works Inc. Sanding clay

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098920A1 (en) * 2001-06-01 2002-12-12 Biogen, Inc. Molecules and methods for inhibiting shedding of kim-1
WO2004060041A2 (en) * 2002-12-30 2004-07-22 Biogen Idec Ma Inc. Kim-1 antagonists and use to modulate immune system
WO2004084823A2 (en) * 2003-03-19 2004-10-07 Abgenix, Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Busse, W. et al. 2001 J. Allergy Clin. Immunol. vol. 108, no. 2, pp. 184-190 *

Also Published As

Publication number Publication date
WO2006094134A3 (en) 2006-10-19
HK1118007A1 (en) 2009-01-30
ATE478707T1 (de) 2010-09-15
BRPI0608254A2 (pt) 2009-12-08
CN101166542A (zh) 2008-04-23
DE602006016413D1 (de) 2010-10-07
IL185653A0 (en) 2008-01-06
KR101213894B1 (ko) 2012-12-20
EP2251037A1 (en) 2010-11-17
EP2251037B1 (en) 2015-01-14
KR20070110411A (ko) 2007-11-16
AU2011202405B2 (en) 2013-03-28
JP2012131825A (ja) 2012-07-12
CA2599967A1 (en) 2006-09-08
EP1865985A2 (en) 2007-12-19
US8206705B2 (en) 2012-06-26
AU2011202405A1 (en) 2011-06-09
WO2006094134A2 (en) 2006-09-08
EP1865985B1 (en) 2010-08-25
IL185653A (en) 2013-04-30
CN103751780A (zh) 2014-04-30
CA2599967C (en) 2014-10-21
US20100150905A1 (en) 2010-06-17
ZA200708372B (en) 2008-12-31
NZ562045A (en) 2010-12-24
AU2006218489A1 (en) 2006-09-08
JP2008531719A (ja) 2008-08-14
US20130089539A1 (en) 2013-04-11

Similar Documents

Publication Publication Date Title
US9205148B2 (en) Antibodies and other molecules that bind B7-H1 and PD-1
JP2008510714A (ja) 多発性硬化症の長期処置
EP4200018B1 (en) Anti-par-2 antibodies and methods of use thereof
AU2014233685A1 (en) Anti-CD52 antibodies
AU2011202405B2 (en) KIM-1 Antibodies for Treatment of TH2-mediated Conditions
JP2024538791A (ja) ＩｇＥ介在性疾患の治療
HK1150360A (en) Kim-1 antibodies for treatment of th1/th2-mediated conditions
HK1118007B (en) Kim-1 antibodies for treatment of th2-mediated conditions
WO2006133286A2 (en) Treatment of tnf antagonist-resistant inflammatory disorders and related methods
MX2007010738A (en) Kim-1 antibodies for treatment of th2-mediated conditions
US20090202562A1 (en) Anti-gfralpha3 antibodies
US20230406951A1 (en) Anti-tnfr2 antibodies and methods of use thereof
US20200239562A1 (en) Anti-il-33 therapy for atopic dermatitis
HK40095177B (en) Anti-par-2 antibodies and methods of use thereof
HK40095177A (en) Anti-par-2 antibodies and methods of use thereof
HK1188230B (en) Human oncostatin m antibodies and methods of use

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired